Hemophilia C in Women

Authors

  • Danka Elena Sobco 1.Lucian Blaga University of Medicine, Sibiu 2.Hematology Department, Emergency Hospital, Sibiu, Romania

DOI:

https://doi.org/10.5281/zenodo.10096623

Keywords:

Factor XI, Rosenthal Syndrome, prolonged bleeding, mutation, fresh frozen plasma FFP, desmopressin, pregnancy, menorrhagia

Abstract

Factor XI (FXI) deficiency (hemophilia C or Rosenthal syndrome) is a genetically-transmitted disease usually inherited in an autosomal recessive pattern associated with genetic defects in the FXI gene. It affects both genders equally, but studies show that the disorder is more common in Ashkenazi Jews. People with hemophilia C do not have spontaneous bleeding, symptoms like uncontrollable or prolonged bleeding, epistaxis, hematuria or bruising occur after serious injuries, major surgeries or after giving birth. In female it may cause menorrhagia. Unless there’s an undergoing surgery or an injury that may cause severe bleeding, people with hemophilia C do not require treatment. Fresh frozen plasma, anticoagulant medication or birth control might reduce the risk of excessive bleeding.1

References

Cleveland Clinic: Hemophilia C

MedScape: Hemophilia C

Berber E. Molecular characterisation of FXI deficiency. Clin Appl Thromb Hemost. 2011;17(1):27-32.

Duga S, Salomon O. Congenital factor XI deficiency. Semin Thromb Hemost. 2009;35(4):416-425.

Askinazi O. Everything You Need to Know About Hemophilia C (Factor XI Deficiency). Healthline. 2023.

Elsevier Rare Diseases. Hemophilia C. 2022.

Steward RG, Saleh OA, James AH, Shah AA, Price TM. Management of Gynecologic Surgery in the Patient With Factor XI Deficiency: A Review of the Literature. Obstet Gynecol Surv. 2012;67(5):291-297.

Gue´guen P, Galinat H, Blouch M-T, et al. Biological determinants of bleeding in patients with heterozygous factor XI deficiency. Br J Haematol. 2012;157(2):245-251.

Rugeri L, Que´lin F, Chatard B, De Mazancourt P, Negrier C, Dargaud Y. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia. 2010;16(5):771-777.

Franchini M. Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency. Haematologica. 2000;85(1):106-107.

Bauduer F, Bendriss P, Freyburger G, Ducout L, Marti B. Use of desmopressin for prophylaxis of surgical bleeding in factor XI-deficient patients. Acta Haematol. 1998;99(1):52-53.

Bauduer F. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study.

Batty P, Honke A, Bowles L, Hart DP, Pasi KJ, Uprichard J, Austin SK. Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres. Haemophilia. 2015;21(4):490-495.

Salomon O, Seligsohn U. New observations on factor XI deficiency. Haemophilia. 2004;10(2):184-187.

Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis. 2005;16(1):37-41.

Rodeghiero F. Management of menorrhagia in women with inherited bleeding disorders: general principles and use of desmopressin. Haemophilia. 2006;12(Suppl 3):21-30.

Downloads

Published

10-11-2023

How to Cite

Sobco, D. E. (2023). Hemophilia C in Women. Hemostasis Thrombosis and Anemic Syndromes, 1(2), 26–29. https://doi.org/10.5281/zenodo.10096623

Issue

Section

Literature Reviews

Categories